Transaction · 0001193125-26-204041

Madigan Catherine

Madigan Catherine, CMO, reported a transaction classified as grant at Hemab Therapeutics Holdings, Inc. involving 49016.000000 shares for an estimated $0.00. Reported holdings after the transaction were 49016.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACMO
COAGHemab Therapeutics Holdings, Inc.
Trade date
Apr 30, 2026
Filing date
May 04, 2026
View on SEC Insider profile
Estimated value$0Shares × reported price
Shares traded49.0k$0.00 per share
Holdings after49.0kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

COAG price since this filing

Daily closing prices, with the filing date and available return windows
COAG · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001193125-26-204041
Stock Option (Right to Buy)
Transaction date
Apr 30, 2026
Filed May 04, 2026, 08:18 PM · 4d delay
Shares
49,016 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
49,016 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership Large Holdings Increase
Filing-only score

-10 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Medical Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The warrant was granted on January 29, 2026. The shares underlying the warrant vest over four years, with 25% of the shares vesting on January 1, 2027 and the remaining shares vesting in equal monthly…

  2. F2

    This option was granted on April 30, 2026. The shares underlying the option will vest over four years in equal monthly installments from May 1, 2026 through May 1, 2030.

Original filing · 0001193125-26-204041
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

COAG